RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Daiichi Sankyo Co Revenue 2024

Daiichi Sankyo Co Revenue

1.6 T JPY

Daiichi Sankyo Co Dividend yield

0.77 %

Ticker

4568.T

ISIN

JP3475350009

WKN

A0F57T

In 2024, Daiichi Sankyo Co's sales reached 1.6 T JPY, a 24.88% difference from the 1.28 T JPY sales recorded in the previous year.

The Daiichi Sankyo Co Revenue history

YEARREVENUE (undefined JPY)GROSS MARGIN (%)
2027e1.9746,51
2026e2.0844,07
2025e1.7751,79
2024e1.657,31
20231.2871,57
20221.0466,19
20210.9664,85
20200.9865,04
20190.9360,78
20180.9663,96
20170.9663,42
20160.9967,70
20150.9264,86
20141.1264,02
2013168,57
20120.9471,38
20110.9770,88
20100.9570,80
20090.8474,54
20080.8873,35
20070.9371,47
20060.9368,60

Daiichi Sankyo Co Aktienanalyse

What does Daiichi Sankyo Co do?

Daiichi Sankyo Co Ltd is a company specialized in the production of medicines. The company was founded in 2005 and was formed from the merger of two Japanese pharmaceutical companies. However, the history of Daiichi Sankyo dates back to 1899 when the Daiichi Group and Sankyo Renkyu merged to form a cooperative. Both companies had been active in the pharmaceutical business since the 1960s and were specialized in the development and production of drugs. Daiichi Sankyo's business model is focused on developing and globally marketing innovative drugs. The company focuses on researching and marketing drugs for the treatment of cancer, cardiovascular diseases, and infectious diseases. Daiichi Sankyo is divided into different divisions. The pharmaceutical division is the company's most important business segment. Here, drugs for various applications are developed and produced, including medications for the therapy of cancer, cardiovascular diseases, and infections. Another division is the medical devices division. Here, medical devices such as catheters and stents for the treatment of cardiovascular diseases, as well as endoscopic devices for the diagnosis and therapy of gastrointestinal diseases, are manufactured. Another important area is the diagnostics division. Here, diagnostic test systems for various applications are developed and manufactured. Some of Daiichi Sankyo's best-known products include the cancer drug Trastuzumab Emtansin and the anticoagulant drug Prasugrel. Daiichi Sankyo is a globally operating company headquartered in Tokyo, Japan. In addition, the company has branches in North, Central, and South America, Europe, Asia, and Oceania. The company places great importance on research and development and participates in numerous collaborations and partnerships with universities and other companies. The goal is to constantly develop new groundbreaking drugs and contribute to the improvement of disease treatment. Overall, Daiichi Sankyo employs approximately 15,000 people worldwide and generates an annual revenue of around 8 billion euros. The company is thus one of the leading companies in the pharmaceutical and medical technology industry and will remain an important player in the global healthcare market in the future. Daiichi Sankyo Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Daiichi Sankyo Co's Sales Figures

The sales figures of Daiichi Sankyo Co originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Daiichi Sankyo Co’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Daiichi Sankyo Co's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Daiichi Sankyo Co’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Daiichi Sankyo Co Stock

How much revenue did Daiichi Sankyo Co generate this year?

Daiichi Sankyo Co has achieved a revenue of 1.6 T JPY this year.

How much was the turnover of the company Daiichi Sankyo Co compared to the previous year?

The revenue of Daiichi Sankyo Co has increased by 24.88% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Daiichi Sankyo Co?

The revenue of Daiichi Sankyo Co is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Daiichi Sankyo Co measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Daiichi Sankyo Co so important for investors?

The revenue of Daiichi Sankyo Co is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Daiichi Sankyo Co pay?

Over the past 12 months, Daiichi Sankyo Co paid a dividend of 35 JPY . This corresponds to a dividend yield of about 0.77 %. For the coming 12 months, Daiichi Sankyo Co is expected to pay a dividend of 35.49 JPY.

What is the dividend yield of Daiichi Sankyo Co?

The current dividend yield of Daiichi Sankyo Co is 0.77 %.

When does Daiichi Sankyo Co pay dividends?

Daiichi Sankyo Co pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Daiichi Sankyo Co?

Daiichi Sankyo Co paid dividends every year for the past 22 years.

What is the dividend of Daiichi Sankyo Co?

For the upcoming 12 months, dividends amounting to 35.49 JPY are expected. This corresponds to a dividend yield of 0.78 %.

In which sector is Daiichi Sankyo Co located?

Daiichi Sankyo Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Daiichi Sankyo Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Daiichi Sankyo Co from 6/1/2024 amounting to 30 JPY, you needed to have the stock in your portfolio before the ex-date on 3/28/2024.

When did Daiichi Sankyo Co pay the last dividend?

The last dividend was paid out on 6/1/2024.

What was the dividend of Daiichi Sankyo Co in the year 2023?

In the year 2023, Daiichi Sankyo Co distributed 28.5 JPY as dividends.

In which currency does Daiichi Sankyo Co pay out the dividend?

The dividends of Daiichi Sankyo Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Daiichi Sankyo Co stock can be added to a savings plan with the following providers: Consorsbank

Andere Kennzahlen von Daiichi Sankyo Co

Our stock analysis for Daiichi Sankyo Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Daiichi Sankyo Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.